Perceptron, the developers of a wide variety of non-contact laser and other specialized inspection and measurement solutions for both commercial and industrial applications, today announced that, as of August 30, the company had sold certain assets and liabilities from their secondary business segment, the Commercial Products Business Unit (CBU) to Inspectron, Inc.
In a move considered as being the best of all possible choices for maximizing shareholder value by management regarding the CBU, which only accounted for 9% of the company’s total sales in fiscal 2012, the sale to Inspectron will allow PRCP to focus squarely on the core Industrial Business Unit (IBU) segment. The CBU was responsible for handling the design and marketing on measurement/detection devices geared towards professional tradespeople in the relevant construction, electrical, mechanic, and plumbing markets.
President of Inspectron, Richard Price, just so happens to be the CBU’s former Senior VP and the deal represents a very smooth transition, with Inspectron being tasked under the terms of the agreement to handle extant business requirements like service parts, warranty obligations, and vendor commitments. Inspectron has thus acquired essentially all pertinent business operations, from inventory and the customer contracts on down the line to patents, tooling, and trademarks for a reported $838k in cash, with PRCP retaining the some $608k in CBU’s accounts receivable balance.
CFO of PRCP, Jack Lowry, pointed to the upcoming scheduled release of fiscal year 2012 financial results (Sept 4) and subsequent earnings call (Sept 5) as an opportunity for investors to get a closer look at the CBU deal, since more information would be offered at that time. The company will be reporting CBU’s financial results as discontinued operations, with the prior year’s data handled on a consistent basis.
Solid move for PRCP that will allow a better treatment of the core business, already known the world over, especially in automotive and manufacturing, where Perceptron’s advanced metrology solutions help speed and stabilize extremely complicated manufacturing processes.
President and CEO of PRCP, Harry Rittenour, explained that a wide range of decisions had come up regarding the secondary segment and been parsed, resulting in this deal. Rittenour further explained that as the IBU accounted for essentially all growth, profitability, and over 90% of total sales from fiscal 2012, the decision to sell off the CBU was really the pick of the litter among other options and offered the best overall valuation for not only shareholders, but PRCP as a whole, including the customer base.
Rittenour expressed a sense of satisfaction over completing the deal and asserted that the strength of the core business over the last year offered profound potential for 2013 and beyond, as the IBU now becomes the sole focus of efforts. This should result in even greater penetration in key global markets where the company has already established itself as an indispensible part of many industrial manufacturing process control workflows. More attention can now be paid to the Value-Added Services aspect of the IBU as well, which provides training and customer support services to help cement client bonds.
For more information on Perceptron, Inc. you can visit the company’s website located at: www.Perceptron.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Friday, August 31, 2012
SEFE, Inc. (SEFE) Exemplifies Movement for Localized Energy Generation
The technologies involved in the generation of useful energy are changing more rapidly than at any time in history. The technologies involved in the transition from wood to coal, and then to oil and natural gas, took far longer than the move to hydro and nuclear power. In historic terms, today’s developments in wind, solar, and other renewable energy sources have occurred in the blink of an eye. And with these most recent developments has come an awareness that our entire approach to power generation may also be changing, away from large scale centralized power plants and hydroelectric dams to far smaller scale production centers serving specific towns, neighborhoods, or even individual homes and buildings.
As efficiencies increase, it becomes feasible for homeowners and private companies to use solar and wind power for isolated application. More than an environmental movement, it is seen as a way to escape dependence upon the grid, although technologies like net metering make grid connection valuable by allowing meters to run in reverse as power is sold back to the grid. In spite of still existing regulatory barriers that can make it difficult for small power generators to fully benefit from their energy contributions, some degree of shift toward multi-source small-scale energy appears inevitable.
For SEFE, developers of one of the most revolutionary energy approaches since the invention of the solar cell, localized power generation is a natural application. The company’s Harmony system taps the earth’s own atmosphere as a source of abundant, clean, renewable, and efficient electrical energy, in virtually any location or weather conditions. The system’s 24/7 capabilities mean that it can be operated independently, in remote locations, and with no connection to the grid, but it is also easily scalable for large applications, powering significant populated areas.
For more information on SEFE, Inc., visit www.SEFElectric.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Sealy Corporation (ZZ) Video Chart for Friday, August 31, 2012
ZZ has pulled back to a recurrent support level around $1.53. The last two bounces off this support resulted in gains between 20 and 30 percent, so technical traders will once again be looking at ZZ to hold the support and generate some upward pressure.
To view the video chart, visit the following link: http://www.missionir.com/videos.html
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Extreme Networks, Inc. (EXTR) Chosen to Supply High Density Switches to Taiwan’s Largest Grid Researcher
The largest and most prestigious research university in Taiwan, Academia Sinica, has chosen Extreme Networks to supply high density, scalable data switches for the university’s network upgrade. A team of physicists within the Academia Sinica Grids (ASG) research area at the university are analyzing the particles created in collisions within the Large Hadron Collider (LHC), the world’s largest and most powerful particle accelerator.
In order to conduct its particle research, ASG needed a 10 Gigabit network that could be increased in size to a 100 Gigabit Ethernet. Extreme Networks’ blade servers met ASG’s needs.
According to Wen-Shui Chen, network manager for ASG, “We were already using Extreme Networks technology, but when we evaluated vendors’ switching gear capable of expanding the network to accommodate HPC architecture, we sought great price-performance backed by fast delivery. Extreme Networks offering ticked all the boxes, and we had experienced excellent service from them in the past. The BlackDiamond® is a great fit for large and dense networks.”
ASG is using Extreme Networks’ BlackDiamond 8900 series fabric switches. These consist of a BlackDiamond 8810 chassis fully loaded with BlackDiamond 8900 module cards. In all, ASG is using more than 2,500 Extreme Networks’ blade servers.
ASG is Extreme Networks’ largest blade server customer in Taiwan, with 52 racks. Boasting more than 5.4 petabytes (5.4 quadrillion bytes) of storage capacity including disk and tape, ASG also represents one of Taiwan’s largest data centers.
“Scientific and research facilities such as Academia Sinica need to be able to analyze immense amounts of real-time data from myriad sources in order to make real-time decisions. Having a flexible, high-performance core network and data center is critical to HPC applications,” said Huy Nguyen, director of product management for Extreme Networks. “An Ethernet-based HPC interconnect like Extreme Networks offers data-intensive organizations a significant advantage due to its cost-effectiveness, ubiquity and open standards.”
In addition to top institutions such as Academia Sinica, Extreme Networks also supports other leading universities and research groups such as the Wellcome Sanger Trust Institute, Johns Hopkins University, and CEA Saclay. Extreme Networks is known as a leader in the high performance Ethernet switching industry. Based in Santa Clara, CA, Extreme Networks has more than 6,000 customers in more than 50 countries.
For more information, visit the company’s website at www.extremenetworks.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, August 30, 2012
SunOpta, Inc. (STKL) Secures WGI Heavy Minerals Acquisition, Anticipates Acquiring Reaming Shares
SunOpta’s mining division, Opta Minerals Inc. announced effective completion of the WGI Heavy Minerals, Inc. acquisition today, with 94% (some 22.28M) of issued and outstanding common shares validly deposited as per conditions set forth in the previously announced offer to acquire at $0.6047/share in cash.
The company considers the deal closed pending the upcoming Sept. 4 deadline for payment on all the shares taken up until that date (and will pay on all such shares until said date). With over 90% of issued and outstanding shares in hand from parties accepting the offer, the company can now move under the British Columbia Business Corporations Act to acquire all outstanding shares not tendered to the offer via the act’s compulsory acquisition provisions. After the compulsory acquisition is done, the company will then move to delist WGI common shares from the TSX and apply for cessation of the relevant reporting issuer requirements in all applicable Canadian jurisdictions.
Given the current status of Opta Minerals as one of the top fully-integrated industrial mineral processor, distributor, and sellers in all of the massive North-American market, the addition of WGI’s infrastructural architecture to the business greatly extends the company’s geographic striking distance and overall product mix. WGI realized some $38.1M in revenues in the most recent fiscal year alone and brings extensive market penetration in industrial abrasive minerals (mostly garnet) to the table.
With a wide global reach already established for their primary abrasives, WGI also has a been carving out a considerable niche in the related area of ultra-high pressure waterjet cutting machine parts/components, which, combined with the vertically integrated process optimization solution capabilities Opta Minerals is known for, creates a real powerhouse in the associated sectors. Opta already has a firm footing as a top solutions provider in custom process optimization, as well as related materials used in areas like steel, foundry, loose abrasive cleaning, and municipal water filtration, with a global production base that stretches from NA, to France and Slovakia. This deal magnifies that footing, amplifying range and effect.
CEO of STKL, Steve Bromley, was pleased at the news of offer condition satisfaction in the WGI deal and asserted to shareholders that the deal would indeed be accretive to ROI, as the fit seems near perfect and should add nicely to overall business/profitability throughput. Successful integration should be a breeze and will help position Opta as a “key global player in industrial minerals,” according to Bromley. A reality which, when fully realized, will further enhance STKL shareholder value.
Opta Minerals also has some key positions in the biofuel area via a minority ownership position in the highly innovative Mascoma Corp., adding further flanking foundation to the Opta Minerals model, with natural pairing to/for the company’s focus on environmentally friendly industrial materials. The addition of WGI will bring real synergy to the already vertically integrated business model and should allow for the propagation of multiple downstream efficiency improvements, some not even fully anticipated yet.
STKL has a 66.2% ownership position in Opta Minerals and has an even larger interest on the other side of the business, a globally-sourced natural and organic food model that even processes/packages, making the other side of the company’s business a self-contained seed-to-shelf entity with its own various processing requirements/competencies.
For more information on SunOpta or to learn more about Opta Minerals, visit either www.SunOpta.com or www.OptaMinerals.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The company considers the deal closed pending the upcoming Sept. 4 deadline for payment on all the shares taken up until that date (and will pay on all such shares until said date). With over 90% of issued and outstanding shares in hand from parties accepting the offer, the company can now move under the British Columbia Business Corporations Act to acquire all outstanding shares not tendered to the offer via the act’s compulsory acquisition provisions. After the compulsory acquisition is done, the company will then move to delist WGI common shares from the TSX and apply for cessation of the relevant reporting issuer requirements in all applicable Canadian jurisdictions.
Given the current status of Opta Minerals as one of the top fully-integrated industrial mineral processor, distributor, and sellers in all of the massive North-American market, the addition of WGI’s infrastructural architecture to the business greatly extends the company’s geographic striking distance and overall product mix. WGI realized some $38.1M in revenues in the most recent fiscal year alone and brings extensive market penetration in industrial abrasive minerals (mostly garnet) to the table.
With a wide global reach already established for their primary abrasives, WGI also has a been carving out a considerable niche in the related area of ultra-high pressure waterjet cutting machine parts/components, which, combined with the vertically integrated process optimization solution capabilities Opta Minerals is known for, creates a real powerhouse in the associated sectors. Opta already has a firm footing as a top solutions provider in custom process optimization, as well as related materials used in areas like steel, foundry, loose abrasive cleaning, and municipal water filtration, with a global production base that stretches from NA, to France and Slovakia. This deal magnifies that footing, amplifying range and effect.
CEO of STKL, Steve Bromley, was pleased at the news of offer condition satisfaction in the WGI deal and asserted to shareholders that the deal would indeed be accretive to ROI, as the fit seems near perfect and should add nicely to overall business/profitability throughput. Successful integration should be a breeze and will help position Opta as a “key global player in industrial minerals,” according to Bromley. A reality which, when fully realized, will further enhance STKL shareholder value.
Opta Minerals also has some key positions in the biofuel area via a minority ownership position in the highly innovative Mascoma Corp., adding further flanking foundation to the Opta Minerals model, with natural pairing to/for the company’s focus on environmentally friendly industrial materials. The addition of WGI will bring real synergy to the already vertically integrated business model and should allow for the propagation of multiple downstream efficiency improvements, some not even fully anticipated yet.
STKL has a 66.2% ownership position in Opta Minerals and has an even larger interest on the other side of the business, a globally-sourced natural and organic food model that even processes/packages, making the other side of the company’s business a self-contained seed-to-shelf entity with its own various processing requirements/competencies.
For more information on SunOpta or to learn more about Opta Minerals, visit either www.SunOpta.com or www.OptaMinerals.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
AcelRx Pharmaceuticals, Inc. (ACRX) Receives U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
AcelRx Pharmaceuticals announced that patents have been approved for “Bioadhesive Drug Formulations for Oral Transmucosal Delivery,” and “Bioadhesive Drug Formulations for Oral Transmucosal Delivery.” The issued patents will provide intellectual property protection for a bioadhesive tablet for oral transmucosal administration of sufentanil through January 2027. AcelRx exclusively owns both patents.
“We have made significant progress this year in establishing our intellectual property portfolio, with five issued US patents now underpinning our novel NanoTab technology,” said Richard King, AcelRx’s President and CEO. “We look forward to building on this success through emphasis on the device aspects of our technology platforms as we seek multiple avenues of protection for our proprietary pipeline of product candidates.”
The first patent provides protection in the United States for each of AcelRx’s four development programs. It also covers AcelRx’s proprietary NanoTab technology for delivering sufentanil with claims to a substantially homogenous bioadhesive tablet which adheres throughout the period of drug delivery, generates a minimal saliva response, and delivers a majority of the drug through the oral mucosa.
The second patent also covers the composition of sufentanil NanoTabs with claims to a bioadhesive tablet for sublingual administration to a subject wherein the bioadhesive material is present at between 2% and 30% by weight, and the tablet generates a minimal saliva response and minimal swallowed drug and delivers at least 55% of the sufentanil through the oral transmucosal route.
Other means to protecting the intellectual property include U.S. patents which claim both methods and compositions directed to sufentanil containing NanoTabs. There is also European patent protection which covers small-volume NanoTab dosage forms for transmucosal administration containing the opioid sufentanil and elements of AcelRx’s dispensing technology and provides patent protection of specific pharmacokinetic parameters derived from sublingual administration using the NanoTab technology. Additionally, AcelRx currently has more than 70 pending patent applications worldwide and continues to file additional new patent applications to further strengthen its market exclusivity.
AcelRx Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx’s lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia, which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery, and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. This product is currently in Phase 3 clinical trials. AcelRx has two additional product candidates which have completed Phase 2 clinical development and plans to initiate a Phase 2 study, pending protocol approval, for a fourth product.
For additional information about AcelRx’s clinical programs please visit www.acelrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Cardium Therapeutics, Inc. (CXM) Scheduled to Make Presentation at the Rodman & Renshaw Annual 2012 Healthcare Investment Conference
Cardium Therapeutics today announced that Chairman & CEO Christopher J. Reinhard will be giving a presentation at the Rodman & Renshaw Annual Healthcare Investment Conference on Monday, September 10, 2012, at 3:15 p.m. Eastern Time. The conference is being held September 9-11, 2012, at the Waldorf-Astoria Hotel in New York City.
An audio webcast of the company’s presentation will be available both live and by replay at http://www.wsw.com/webcast/rrshq22/cxm as well as the Investors section of Cardium’s website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-calendar. An updated investor presentation is now available on Cardium’s website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.
Cardium Therapeutics is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium’s current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company’s in-house MedPodium Health Sciences healthy lifestyle product platform.
To learn more about the company, visit www.cardiumthx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Selectica, Inc. (SLTC) Guided Selling Recognized as a Finalist in the Best New SaaS or Cloud Computing Product Category
Selectica, a provider of software that improves sales cycles and streamlines contract processes, has been acknowledged as a finalist in the 4th Annual 2012 Golden Bridge Awards for the Best New SaaS or Cloud Computing category for its Selectica Guided Selling cloud-based offering.
“Selectica Guided Selling empowers growing companies and their sales channels to accurately map customer needs to their solutions, and protect margins by enforcing pricing and approval policies,” said Kamal Ahluwalia, Chief Strategy Officer at Selectica. “We’re honored to have the Golden Bridge Awards acknowledge our mission to deliver this patented, cloud-based sales technology to a broader market.”
When Selectica Guided Selling was released in February 2012, customers had the opportunity to apply the patented configure-price-quote software integrated with Selectica Contract Lifecycle Management to guide them from configuration to quote to contract. Selectica Guided Selling allows companies to easily define and maintain rules to guide the sales process. After rules are established, sales teams are able to configure deals within a step-by-step selection environment, driven by a declarative constraint engine that dynamically includes or eliminates choices based on user input.
The Golden Bridge Awards serve to recognize the finest companies of all types and sizes across the globe in categories such as Best Products, Innovations, Management and Teams, Women in Business and the Professions, and PR and Marketing Campaigns. Companies will be formally honored in San Francisco, California, on Tuesday, October 2, 2012, during the fourth annual awards dinner and presentation.
For further information, please visit www.selectica.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Medicinova, Inc. (MNOV) is “One to Watch”
MediciNova is a biopharma developer which has steadily built up a portfolio of diverse clinical and preclinical candidates in the novel, small molecule therapeutics space by pursuing an aggressive strategy of forming strategic alliances with other pharma developers (primarily Japanese). This in-licensing strategy born out of the company’s ability to successfully cultivate business relationships with key industry developers, both in Japan and around the world, has granted MNOV the rights to some very strong product candidates.
MediciNova currently has two prominent, core candidates, alongside four other clinical-stage compounds and two pre-clinical targets. While the company is constantly working at the entire portfolio, as well as seeking out new candidates in other unmet or underserved areas, with commercial emphasis on developing for U.S. markets, MNOV is currently heavily focused on developing their two most promising core candidates MN-221 and Ibudilast (MN-166/AV411).
MN-221 was identified by and is being developed for its profound impact capability in combating acute exacerbations of asthma (prolonged episodes of asthma characterized by not responding to standard bronchodilator/corticosteroid therapies) and COPD (chronic obstructive pulmonary disease). While a variety of beta-agonist agents exist, typically offered in inhaler format, severe cases, and the worsened condition of COPD which becomes an underlying condition, are essentially unmet, with an alarming number of cases eventuating in hospitalization and a significantly higher mortality rate. MN-221 is a novel, highly-selective receptor agonist, acting as a high-performance beta(2)-adrenergic receptor agonist in lung tissue and thanks in large part to the selectivity, a vastly superior agonist in beta(1)-adrenergic receptors in heart tissue as well, making it superior to extant, less selective beta(2)-adrenergic receptor agonists currently out there (as shown in extensive Phase II/IIa clinical trials).
CDC data clearly indicates the size of the market, with asthma-related emergency visits rising over 13% between 1992 and 2006 despite sweeping advances in asthma treatment options. This shows a strong correlation to the company’s market analysis, with the 440k asthma-related hospital discharges in 2006 alone boldly underlining the existence of a large, unmet demand segment that, unfortunately, also showed some 2.5k deaths in 2006. Furthermore, National Heart, Lung and Blood Institute data shows asthma-associated total direct hospital costs in 2007 were $4.7B in the U.S. alone. It should be readily apparent that even without adding in the relevant COPD data, there is a massive market here being largely ignored. COPD data from the American Lung Association places direct/indirect costs at around $26.7B and $15.9B respectively for the same year, adding to the obviousness of an unmet medical need for precisely the kind of safe, effective treatment MN-221 represents.
The recent August 23, 2012 news release by MNOV offered further positive data from a multi-day, repeat-dose clinical trial of MN-221 in stable, moderate-to-severe chronic COPD patients. The preliminary pharmacokinetic and efficacy findings, combined with the absence of any clinically significant safety concerns, in light of the demonstrated ability to produce improved pulmonary function, means MNOV potentially has its hands on a real winner.
Turning to the second core candidate Ibudilast (MN-166/AV411), we have a portfolio including MN-166 which could be a real multiple sclerosis treatment and the first-in-class AV411 Phase II-staged compound, as well as its proprietary analogs for neuropathic pain and drug addiction. Already approved in Japan for over 20 years (cerebrovascular disorders and bronchial asthma), ibudilast is considered an NME (new molecular entity) in the U.S. and Europe, but has been prescribed to over 1M patients in Japan and elsewhere for the other indications with solid safety returns. With broad applications in various anti-inflammatory, glial attenuating capacities, this group of drugs has seen trialing in neuropathic pain and could evolve into a powerful multiple sclerosis treatment (which is just a systemic central nervous system inflammation ultimately), also seeing extensive trialing/studies in opioid-induced withdrawal and even methamphetamine addiction.
The other non-core candidates MNOV has in its holster range from targets in bladder disease (interstitial cystitis, MN-001) and even solid tumor cancers (MN-029), to premature birth/preterm labor prevention (MN-221), urinary incontinence (MN-246), and anxiety disorders (MN-305). MN-305 is something to think about in particular, because when one looks at the extremely lucrative anti-depressant and SSRI space (selective serotonin reuptake inhibitor), it is immediately apparent that a safer offering without the serious side effects, especially if it is fast-acting instead of taking up to weeks to kick in, could alone drive shareholder returns. MN-305 benefits from the same orally bioavailable compound properties found throughout the MNOV portfolio’s other candidates and this fact alone makes the commercialization vectors tantalizing.
To get a closer look at this dynamic biopharma developer, take a look at the company’s website located at: www.MediciNova.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Construction Begins on Entertainment Gaming Asia, Inc. (EGT) Slot Hall Project
Today, Entertainment Gaming Asia announced that it has commenced construction of Dreamworld Poipet, its slot hall development project in Poipet, Cambodia. The leading gaming company is focused on emerging gaming markets in Pan-Asia, and this project is strategically located at one of Cambodia’s most significant border crossings with Thailand. It will be a standalone slot hall constructed as an extension of an existing popular casino.
The Dreamworld Poipet slot hall will measure approximately 16,000 square feet and feature a comprehensive suite of 300 high-quality gaming machine seats. The machines include multi-player electronic tables and other top-of-the-line features to provide players a first class casino experience. At $7.5 million, the project is internally funded and is expected to open in early 2013.
Clarence Chung, Chairman and CEO of Entertainment Gaming Asia, remarked, “We are pleased to begin construction of our Dreamworld Poipet project. With a focus on providing quality gaming products, superior customer service and inviting atmosphere, we are dedicated to making Dreamworld Poipet a quality leader in this market. Our entrance into the established and growing gaming market of Poipet is a positive step in our strategy to become a leading developer and operator of regional casinos and gaming venues in Indo-China.”
The company also announced that it has launched a “Dreamworld Poipet Updates” section on its website that will allow interested parties to keep track of the project’s development. Entertainment Gaming Asia will provide periodic updates and photos at www.EGT-Group.com under the section entitled “Dreamworld Projects.”
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Salem Communications Corp. (SALM) Declares Third Quarter Dividend
Salem Communications today announced that its board of directors has declared a dividend for the third quarter of 2012 in the amount of $0.035 per share of its Class A and Class B common stock. The cash dividend will be paid on September 28, 2012, to all common stockholders of record as of September 14, 2012.
Salem Communications is the largest commercial U.S. radio broadcasting company that provides programming targeted at audiences interested in Christian and conservative opinion content. Upon completion of all announced transactions, Salem will own and/or operate a nationwide portfolio of 97 radio stations in 37 markets. These include 61 stations in 22 of the top 25 markets in the U.S.
The company also owns the Salem Radio Network, a national radio network that syndicates talk, news, and music programming to approximately 2,000 affiliated radio stations and also programs the Family Talk Christian-themed talk format on SiriusXM Channel 131. Additionally, it owns Salem Media Representatives, a national media advertising sales firm with offices across the country.
In addition to these businesses, Salem Communications owns an internet and publishing division. Salem Web Network is a provider of online Christian and conservative-themed content. Its includes websites such as www.Christianity.com, www.Jesus.org, www.Crosswalk.com, www.BibleStudyTools.com, www.GodTube.com, www.WorshipHouseMedia.com, www.OnePlace.com, www.Townhall.com, and www.HotAir.com. It also circulates Christian and conservative magazines such as HomeComing The Magazine, YouthWorker Journal, The Singing News, FaithTalk Magazine, Preaching Magazine, and Townhall Magazine.
For further information about Salem Communications and its operations, please visit the company’s website at www.salem.cc
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, August 29, 2012
Trovagene, Inc. (TROV) Receives Milestone Payment from Ipsogen S.A.
Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell deaths that cross the kidney barrier and can be detected in urine. The company is leveraging its intellectual property through out-licensing agreements.
The company today announced that it has received a milestone payment from Ipsogen S.A., a subsidiary of Qiagen N.V. (Nasdaq: QGEN). This payment comes from a co-exclusive license agreement to manufacture and sell diagnostic kits for the detection of nucleophosmin protein (NPM1) mutations in patients with acute myeloid leukemia (AML). The payment was triggered by issuance of U.S. Patent 8,222,370 that is part of a family of patents filed by Trovagene around nucleophosmin protein that cover NPM1 mutations in AML.
AML is a clinically heterogeneous disease with about 200,000 new cases per year worldwide. Subgrouping of AML patients using chromosomal abnormalities provides for more individualized patient prognosis. But in nearly half the cases, the chromosomes appear normal and provide no guidance to doctors. However, a discovery by Drs. Brunangelo Falini and Cristina Mecucci at the Institute of Hematology at the University of Perugia in Italy showed that many AML patients have mutations in the NPM1 gene and that these mutations are a marker for more favorable clinical outcomes.
The National Comprehensive Cancer Network, which sets clinical standards for cancer treatment, has now included testing for NPM mutations in their clinical practice guidelines. To date, it has granted nonexclusive sublicenses to offer mutation analysis of NPM1 as a laboratory service to Laboratory Corporation of America Holdings, InVivoScribe Technologies, Warnex Medical Laboratories, Fairview Health Services of Minneapolis, Minnesota, and Munchner Leukamielabor GmbH in Munich, Germany. The company also has granted co-exclusive licenses to manufacture and sell NPM1 mutation assays to Ipsogen and Asuragen, Inc.
For additional information about Trovagene and its intellectual property, please visit the company’s website at www.trovagene.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The Case for Duma Energy Corp. (DUMA)
Unlike typical energy exploration and production companies, Houston’s Duma Energy Corp. is based on far more than hopes for a successful well. The company has a growing list of assets in both the U.S. and overseas, with expanding income and proven reserves necessary to sustain the company for the long haul.
• Duma’s key productive interests are located in the shallow waters in Galveston Bay and Trinity Bay comfortably near Houston. It also has interests in wells and sites in two other parts of Texas, as well as in Louisiana and Illinois.
• The company produced 38,000 barrels of oil equivalent (boe) in fiscal 2011, and has already produced over 45,000 boe in the first half of fiscal 2012, with recent year-over-year revenue growth exceeding 500%. Operating margins, now near 50%, are improving as new wells and production increase efficiencies.
• Duma has $77.7 million in proven reserves (discounted), with less than $12 million booked reserves.
• The company has a time-tested team leading it, with most of the invested capital coming directly from the CEO and insiders. As such, the company targets only industry standard and proven technologies, carefully avoiding risky plays that depend upon high commodity prices.
• In addition to productive and promising projects in the U.S., Duma now holds a working interest in a petroleum concession of approximately 5.3 million acres in the southwestern African nation of Namibia. The concession is located in the Owambo Basin, a huge area that extends across the northern border into Angola, one of Africa’s major oil producing countries. As part of the company’s strategy, overseas exploration efforts are well-funded through its ongoing and stable domestic production operations in the U.S.
In summary, Duma has growing revenue, cash flow, and a solid pipeline of prospects.
For additional information on Duma Energy, visit the company’s website at www.DUMA.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Longhai Steel, Inc. (LGHS) to Reach Full Capacity at New Steel Wire Facility by Yearend
Longhai Steel, a producer of high-quality steel wire products in the People’s Republic of China, announced this morning that the company has completed testing of its initial production of high quality steel wire. Management anticipates ramping up production to full capacity by the end of 2012.
“We are pleased with the testing results from the initial production at our second facility,” stated Steven Ross, Executive Vice President of Longhai Steel. “We have met or exceeded all of our internal performance metrics and look forward to expanding our customer base and broadening our end market footprint.”
Longhai Steel’s growth strategy includes capitalizing on government actions aimed at encouraging industry consolidation via the acquisition of neighboring producers at attractive valuations. The company also plans to grow organically through capacity expansion, broadening its product portfolio, improving operating efficiencies, and continued expansion of technical expertise.
To learn more about the company, visit www.longhaisteelinc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Penn Energy and Canadian Solar, Inc. (CSIQ) Sign Deal Worth 18.7 Megawatts
Canadian Solar yesterday announced that its subsidiary, Canadian Solar Solutions, Inc., has closed a deal with Penn Energy Renewables that will see the construction of two new solar energy farms in Ontario, Canada. The construction will begin in the third quarter of 2012 and will produce 18.7 MW.
Billing itself as “one of the world’s largest solar companies,” Canadian Solar is focused on the design and manufacture of solar power systems for use both on and off grid. The company also supplies parts for solar applications, such as ingots, wafers, solar cells, and solar modules. Canadian Solar has offices in North America, Europe, Australia, and Asia.
Collectively, the two new solar farms are anticipated to supply enough electricity to power 2,600 homes; the construction of the farms will create 100 new jobs in construction, manufacturing, and engineering. Furthermore, the solar farms are expected to prevent approximately 432,000 metric tons of carbon dioxide emissions over a twenty year period.
Sean McCloskey at Penn Energy Renewables Ltd., said, “We are committed to developing and operating utility-scale solar PV projects that provide clean, infinitely renewable solar energy to the homes, businesses and schools in the communities that we serve. As a developer and long-term investor in solar PV projects, we were impressed with Canadian Solar’s full array of offerings, which include modules manufactured in Ontario, EPC services and the provision of long-term operations and maintenance services.”
Shawn Qu, chairman and CEO of Canadian Solar, added, “We believe strong companies, like Penn Energy, want to work with Canadian Solar because of our track record, expertise, bankability, photovoltaicpanel reliability, and global brand name. As a result, we have built an impressive portfolio of projects and have a very robust pipeline of attractive projects in Canada, the U.S. and Asia. We believe that we have a strong position in Ontario and each project that we complete builds on our lead as the most experienced and dependable developer in Ontario to take a project from development stage to full operation.”
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
China Botanic Pharmaceutical, Inc. (CBP) to be Granted New Invention Patent in China
China Botanic Pharmaceutical recently announced that the State Intellectual Property Office of the People’s Republic of China (SIPO) will be granting the company a new invention patent on its comprehensive method to enhance the medicinal value of Schisandra, a key component in its pharmaceutical products. The company expects to receive the patent certificate by October 2012.
China Botanic filed Patent Application No: 201010119861.3 in February 2010, which was followed by a two-year comprehensive review conducted by the SIPO. Upon grant of the new patent, the company anticipates securing market exclusivity for a period of 20 years.
Research in China suggests that Schisandra is a wild plant with significant medical and health benefits. Schisandra has been found to prevent liver damage and is an effective sedative for treating insomnia and central nervous system depression. China Botanic’s comprehensive method enables it to obtain a number of compounds out of Schisandra, including lignin, polysaccharides, vitamins, and organic acids.
China Botanic’s Chairman and CEO, Mr. Shaoming Li, remarked, “Schisandra is one of the important components for our anti-depression and nervous system regulating products. We look forward to receiving the new patent in October, which will further support our research and development of Schisandra, development of Schisandra-based new medicines and strengthen our ability to leverage the potential of Schisandra. In addition, our continued success in obtaining new patents and our commitment to invest into research, development and talent defines our long-term growth strategy. We believe that in the foreseeable future, our new patent will favorably contribute to our business performance.”
For more information on the company, visit www.renhuang.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Axcelis Technologies, Inc. (ACLS) Announces High Volume Follow-On Order from Major Chipmaker
Axcelis Technologies, a leader in supplying innovative, high-productivity solutions for the semiconductor industry, has announced its receipt of a multiple system follow-on order for its Integra RS plasma dry strip system from one of the leading semiconductor manufacturers in the world. The systems, which began shipping this month, will be utilized in the production of 3x nm and below NAND Flash devices at leading-edge fabs in Asia and the United States.
Axcelis is pleased to expand its installed base in working with this industry leader and supporting its evolving manufacturing needs. The Integra dry strip system has shown superior manufacturing productivity for Axcelis’ memory customers, combined with process technologies that are extendable to the most advanced device nodes. Customers value the system’s ability to efficiently handle standard dry strip processes, together with critical cleaning steps over sensitive exposed metals on a single modular wafer handling platform. This distinctive combination of productivity and process performance makes the Integra an ideal choice for the high volume manufacturing of leading-edge memory.
A recognized leader in plasma cleaning and dry strip technology, Axcelis supplies systems that are known around the world for their innovative process solutions, leading reliability and low cost of ownership. The company’s portfolio of dry strip cleaning products includes the Integra RS and ES systems, as well as the Rapidstrip 320 and 210 systems. Together, these products deliver plasma cleaning technology that is highly differentiated and meets the full range of customer needs – from the highest productivity, non-oxidizing solutions for 28nm and below to single chamber, small substrate size applications in the MEMS, LED and packaging markets.
Axcelis Technologies is headquartered in Beverly, Mass. The company provides innovative, high-productivity solutions for the semiconductor industry. Axcelis is focused on developing enabling process applications through designing, manufacturing, and completing life cycle support of ion implantation and cleaning systems.
For more information, visit the company’s Web site at www.axcelis.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tuesday, August 28, 2012
Rockwood Holdings Snaps Up Lithium Ore Producer Talison Lithium Ltd. (TLH.TO)
Australian-based Talison Lithium, the world’s largest producer of lithium ore, was acquired in an offer from specialty chemicals company Rockwood Holdings, which is buying the company for C$724 million. Rockwood is paying more than 33 times Talison’s EBITDA earnings and more than double the mark-up of non-ferrous metal company takeovers which have occurred in the past two years.
Talison has been producing lithium ore at its Greenbushes mine in Western Australia for more than 25 years and accounts for one-third of the global market for lithium ore. The company has doubled production at its main mine and has increased prices this year for the ore by 25%. About one-quarter of lithium globally is extracted from ore-based reserves such as those operated by Talison and another Australian company, Galaxy Resources. The remainder comes from brine-based resources located mainly in South America.
Lithium is, of course, the key ingredient in lithium-ion batteries which are used in a variety of consumer electronic products, including mobile phones, tablets, and laptops, in addition to many electric car batteries. Other uses include playing an increasingly key role in the development of solar energy storage and in grid stabilization.
Demand for lithium ore has been growing by more than 20% a year since 2000. And this growth rate is expected to soar even higher beginning around 2015; not only as the number of electronic devices increases but as the rollout of electric vehicles around the world begins to accelerate and as lithium-ion batteries are deployed in large numbers in electricity grids and for storing solar energy.
For additional information about lithium and the takeover offer, please visit either www.talisonlithium.com or www.rockwoodspecialties.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Neuralstem, Inc. (CUR) Announces Completion of Initial NSI-566 Injections
Neuralstem, a biopharmaceutical company, continues its work on a cure for ALS, amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease. Beginning in January, 2010, Neuralstem has been transplanting its NSI-566 spinal cord neural stem cells into patients that can and cannot walk, Phase I of its NSI-566 testing. The Phase I testing was designed to inject the sample cells into 18 patients and has taken place at the Emory ALS Center in Atlanta. The principal investigator in the trial is Eva Feldman, MD, PhD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System.
Yesterday, Neuralstem reached another milestone in its Phase I testing. Neuralstem announced it had injected the NSI-566 cells into the 18th patient. The eighteenth patient is the third to return to the trial for an additional set of injections. This patient is also the final patient in the Phase I portion of the trial as it is currently designed. The Phase I portion of the trial is scheduled to conclude six months after this final surgery.
Asked to comment, Karl Johe, PhD, Chairman of Neuralstem’s Board of Directors and Chief Scientific Officer said, “We are delighted to have completed Phase I in this groundbreaking trial, the first approved by the FDA to test neural stem cells in patients with ALS.”
“There have been many firsts in this trial, including the first lumbar intraspinal injections, the first cervical region intraspinal injections, and the first cohort of patients to receive both,” stated Jonathan D. Glass, MD, Director of the Emory ALS Center. “This has required incredible effort from the Emory medical and support team and I wish to express my thanks to all of them, as well as to acknowledge the generosity and courage of the patients and their families.”
Dr. Feldman, an unpaid consultant to Neuralstem, added,”[w]e have found the procedure to be extremely safe.” She continued, “In some patients, it appears that the disease is no longer progressing, but it is too early to know if the result from that small number of patients is meaningful.”
After testing via lower spine injections, the trial advanced to transplantation in the cervical (upper back) region of the spine. The first cohort of three was treated in the cervical region only. The last cohort of three received injections in both the cervical and lumbar regions of the spinal cord. In an amendment to the trial design, The Food and Drug Administration (FDA) approved the return of previously treated patients to this cohort. The entire 18-patient trial is set to conclude six months after the final surgery.
Neuralstem’s patented technology gives it the power to produce neural stem cells of the human brain and spinal cord in commercial quantities. Neuralstem has the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia, which are supportive cells in the central nervous system.
The company is also focusing on major central nervous system conditions with its cell therapy platform. Neuralstem is looking to cure spinal cord injury, ischemic spastic paraplegia, and chronic stroke. In fact, the company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.
Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain’s capacity to generate new neurons. If the brain has the capacity to generate new neurons, this could potentially reverse the pathologies of some central nervous system conditions.
The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). NSI-189 might also be effective in treating chronic traumatic encephalopathy (CTE), Alzheimer’s disease, and post-traumatic stress disorder (PTSD).
Neuralstem, Inc. was founded in 1996 and is headquartered in Rockville, Maryland.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Sonus Networks, Inc. (SONS) Successfully Completes Acquisition of Network Equipment Technologies
Sonus Networks, an enabler of cloud-based unified communication, completed the acquisition of Network Equipment Technologies (NET). This acquisition expands the Session Border Controllers Portfolio, opening new channels. NET provides engineering resources, broader channel capability, and a broad U.S. Federal Government installed base to leverage into SIP-enabled platforms. Integration plans for customer-facing operations will be executed immediately.
“The completion of the acquisition of NET represents an important milestone for Sonus as it enables us to serve the enterprise market with a comprehensive portfolio of SBC solutions,” said Ray Dolan, president and CEO of Sonus Networks. “The addition of NET also brings Sonus a very talented workforce across engineering, sales and services that can accelerate our ability to lead the market transition to Cloud-based Unified Communications.”
By combining portfolios, customers are now provided with an end-to-end SBC platform for SIP-enabled unified cloud communications. This product has also been Microsoft Lync certified, which will allow companies to deploy throughout the entire network.
Sonus provides next-generation unified cloud computing solutions through secure, reliable, and scalable IT networks. Sonus has over 15 years of experience transforming networks to IP, and enables customers to capture and retain users and generate significant ROI. Sonus products include session border controllers, policy/routing servers, subscriber feature servers, and media and signaling gateways. Sonus products are supported by a global services team with experience in design, deployment, and maintenance of some of the world’s largest and most complex IP networks.
For more information, visit www.sonus.net
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Daegis, Inc. (DAEG) Announces Key Enhancements to eDiscovery Platform
Daegis, a prominent provider of eDiscovery solutions, announced that it has made significant enhancements to the Daegis eDiscovery Platform. The improvements will offer more control of the eDiscovery process to users, provide enhanced search functionality, as well as add the ability to ingest and export data. This combination allows for superior flexibility in data management across the Electronic Discovery Reference Model (EDRM).
Data from IBM indicates that an incredible 2.5 quintillion (2.5 x 1018) bytes of data will be created every single day in 2012. This astounding expansion of electronically stored information from a multitude of sources, including email, social media, and mobile data, has caused eDiscovery practices to transition from a matter-by-matter to a data-driven approach requiring new technologies such as Daegis’ Cross-Matter Management methodology and innovative Master Repository. Daegis’ data driven approach will be become even more efficient and powerful as a result of the combination of new self-service methods for ingestion and export and bolstered search capabilities.
“As the volume and variety of data continue to escalate exponentially, attorneys are attempting to control costs by moving away from reinventing the wheel for each case with traditional, reactive, matter-specific eDiscovery,” said David Horrigan, eDiscovery and Information Governance analyst at 451 Research. “Corporate legal departments are embracing cost-cutting, data-driven models to analyze and manage data proactively across multiple matters rather than starting from scratch for each new case. This type of legal business model–and the platforms able to support it–will improve consistency both in search results and attorney review calls, thus delivering more defensible and affordable eDiscovery.”
Features of the Daegis eDiscovery Platform increasing user control include:
• Ingestion: The new self-ingestion feature allows clients to assemble data themselves and immediately upload batches of data directly to Daegis’ eDiscovery Platform via any internet connection. This new approach provides full transparency and security over the uploading of data while giving users the flexibility to immediately upload data needed for a project or a new matter.
• Export: Self-export enables users to export data from the platform to review small portions of a larger data set, create a discrete set of documents for expert witnesses, generate reports, and to transfer data to a separate location for further analysis. The introduction of new user-managed export tools allows clients to locate and process case materials for export and productions themselves.
• Iterative Search: Allows users to refine and validate a set of search criteria multiple times, making changes each time until an acceptable rate of responsive results are returned. The iterative search process adds tracking, reporting, and measurability to allow clients to target the most relevant document set for review while returning as few over and under inclusive results as possible. Changes to search criteria are recorded and saved to aid in the audit and defensibility of the search should it ever come into question.
• Enhanced Export for Lotus Notes Email: Enables users to export native Lotus Notes (NSF) email in expanded formats of EML, MSG, HTML, or TXT. Clients with Lotus Notes data can search and review documents leveraging the complete fidelity of native Lotus Notes, as well as export or produce those documents in different formats to meet the requirements of other parties or third party tools.
• CaseMap Integration: Daegis also offers powerful and flexible CaseMap integration, allowing clients to leverage information in Daegis’ eDiscovery Platform for their case organization and analysis.
“It is rewarding to see industry recognition of data-driven eDiscovery, as Daegis has long been a front-runner in both the vision of that approach and the execution of it through our technology platform,” said Deborah Jillson, President of Daegis. “The new features we’ve included in our software go a long way towards helping legal teams improve workflow and achieve even greater cost savings and control of what can be a very time-intensive and costly business process.”
For more information, please visit www.daegis.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
SEFE, Inc. (SEFE) Announces Retirement of 4.5 Million Shares of Common Stock
SEFE, a sustainability company engaged in offering innovative, pioneering solutions for the world’s energy needs, just announced that it has retired 4.5 million shares of common stock. As a result, the number of common shares issued and outstanding has been reduced by approximately 8%.
According to the press release issued by SEFE this morning, the retirement of these shares occurred in connection with a Separation and Release Agreement involving the company and a former director. Immediately following the exchange and retirement of the common shares, the number of common shares issued and outstanding was reduced from 59,583,575 to 55,083,575. The DTC float is now 13,774,000, and the number of authorized shares is 200,000,000.
Don Johnston, CEO of SEFE, stated, “The retirement of these common shares is a very positive step toward improving our Company’s overall capital structure and enhancing value for both new and existing shareholders.”
To learn more about the company, visit www.sefelectric.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Monday, August 27, 2012
ZBB Energy Corp. (ZBB) Appoints Tony Siebert as VP – Sales and Product Marketing
Friday, ZBB Energy announced that Tony Siebert has been appointed as the company’s Vice President of Sales and Product Marketing. Mr. Siebert will assume full responsibility of the coordination of ZBB’s sales and product marketing strategy.
In connection with his appointment, Mr. Siebert was awarded inducement options to purchase a total of 200,000 shares of ZBB’s common stock. 50,000 of these options will vest based on the achievement of certain performance targets; the remaining 150,000 of these options will vest over three years.
Eric C. Apfelbach, President and CEO of ZBB Energy, remarked, “We welcome Tony to our growing team. Tony’s energetic sales approach and marketing experience bring the exact talents we need to grow our product sales as we move into broader commercialization. He has a proven track record of building worldwide teams that can increase sales and maintain focus on providing solutions that exceed customer expectations.”
Mr. Siebert has over 20 years of experience in sales and engineering in the utility and industrial industries. He has served as Managing Director of Grid Sales for American Superconductor Corporation (AMSC) where he was responsible for the management of sales of its grid products worldwide. He was also the Director of the FACTS and DVAR businesses where he was responsible for grid sales, business/product development, engineering prioritization, and coordination of project management.
Prior AMSC, Mr. Siebert held senior sales, business development, and engineering roles at ABB Power Electronics Division. Mr. Siebert graduated from Milwaukee School of Engineering with a Bachelor of Science degree in Electrical Engineering Technology.
“ZBB has the right products to provide the best solutions for a growing global infrastructure problem,” said Tony Siebert. “I look forward to leading the worldwide sales team and helping ZBB dramatically increase sales and backlog to meet and exceed the Company’s goals.”
For more information, visit www.zbbenergy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
SEFE, Inc. (SEFE) Ready to Conduct High Voltage Experiments with Newly Constructed Test Chamber
SEFE, a sustainability company engaged in offering innovative, pioneering solutions for the world’s energy needs, today announced the construction of a 12’ x 12’ x 24’ Faraday cage test facility at its headquarters in Boulder, Colorado. The cage will serve as an isolated test platform for conducting high voltage experiments.
Grounded to prevent charge build-up and to protect against high voltage arcs, the cage is constructed as a wood frame wrapped with metal hardware cloth capable of shielding external electric fields from DC to 10 GHz. The team has received and is currently installing a high voltage power supply (up to 150kV), transformer, and various supporting test equipment on loan from the LECGlobal R&D laboratory.
“This equipment will be used for numerous R&D activities,” stated SEFE CEO Don Johnston. “Tests to be performed in the Faraday cage include characterization of corona discharge air terminals, ground-based electronics such as oscillator circuits and spark gaps, and simulation of the earth-field antenna up to 4500’ elevation for comparison with field tests that use balloons. Most importantly, this test facility will allow us to observe the behavior of the balloon collectors in a laboratory setting.”
For more information, visit www.SEFElectric.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Shiner International, Inc. (BEST) Video Chart for Monday, August 27, 2012
BEST is a low-volume play that is holding a firm base at 17 cents. The chart is currently on radar to make a larger move; whether that is to fall through support or continue to make the shift to bullishness.
To view the video chart, visit the following link: http://www.missionir.com/videos.html
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
AdCare Health Systems, Inc. (ADK) Signs Definitive Purchase Agreement for South Carolina Skilled Nursing Facility
Leading long-term care provider AdCare Health Systems announced it has signed a definitive purchase agreement to acquire a skilled nursing facility in South Carolina for $4.2 million.
The facility, which generates an estimated $3.8 million in gross annualized revenues according to its latest financials, has 84 beds in service. It is anticipated that the acquisition will be completed in the fourth quarter of 2012. AdCare intends to finance the acquisition of the facility through a traditional bank loan.
With AdCare’s current annualized run-rate, combined with transactions in the process of closing, the company’s estimated annualized revenue run-rate is anticipated to exceed $280 million, which would represent an increase of more than 84 percent over its 2011 revenues and an increase of more than 10 times its revenues since initiating its M&A campaign. This latest transaction supports AdCare’s aggressive M&A strategy of targeting skilled nursing properties that are underperforming, for the purposes of facility optimization. The company’s optimization strategy involves leveraging its regional teams to increase facility occupancy and Medicare census, in addition to optimizing reimbursement and patient care. AdCare expects this strategy to generate a substantial increase in revenues.
This latest signing brings the total number of facilities AdCare has put under contract to 48 since the company’s current M&A program began. This M&A program, along with integrating the new facilities, remains AdCare’s primary focus in the second half of 2012, as the company continues evaluating a number of opportunities in the Southern region of the United States that fit its acquisition strategy. The company plans to complete the acquisition of at least eight additional facilities in the second half of 2012, which include the facility announced today, an additional facility in South Carolina, and six facilities in Oklahoma.
AdCare Health Systems is a renowned innovator in senior living and healthcare facility management, owning and managing long-term care facilities and retirement communities. Since the company was created in 1988, its aim has been to provide elderly patients with the highest quality healthcare services, including an array of skilled nursing and sub-acute care services.
For more information, visit the company’s Web site at www.adcarehealth.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
SORL Auto Parts, Inc. (SORL) Unveils Power Steering Pump for the Chinese Electric Bus Market
SORL Auto Parts, a leading global supplier of brake and control systems to the global commercial vehicle industry, today reported that it has launched its newly developed, electrically controlled power steering pump, marking a technological breakthrough for the global electric bus market. SORL’s new power steering pump is more energy and cost efficient, environmentally friendly and has higher efficiency and a longer life span than traditional hydraulic power steering pumps. Installation and maintenance of the pump is effortless due to its small size and compact structure.
New energy electric vehicles are a focus of the Chinese government as it attempts to reduce carbon emissions and air pollution across the country. SORL has a long-term research and development program designed to position the company as the leader in developing electrically controlled auto parts for electric vehicle manufacturers worldwide. Just last month, the company launched its new generation of electric air brake compressors designed to be used in electric buses.
According to Chinese government plans, by 2015, there will be production and sales of over 500,000 electric and hybrid vehicles. And by 2020, the target is for Chinese production capacity of electric and hybrid vehicles to exceed 2 million vehicles. SORL’s mission is to help China’s government reach its goal by increasing the technological level of the Chinese auto industry with the introduction of more electrically controlled auto parts.
For further information on SORL Auto Parts and its breakthrough technologies, please visit the company’s website at www.sorl.cn
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Longhai Steel, Inc. (LGHS) Well Positioned to Execute Expansion Strategy
Located in Hebei Province, where most of China’s steel is produced, Longhai Steel has captured a great deal of attention and considerable market presence for its ability to fulfill orders in rapid succession within a highly competitive price structure and at a better quality than other suppliers in the People’s Republic of China, or PRC.
Subsequent to a facility expansion, Longhai Steel increased its yearly production by 67 percent in the fourth quarter of 2011, going from 900,000 to 1.5 million metric tons of high quality steel wire, in diameters from 5.5 millimeters to 18 millimeters, with production taking place on technologically superior equipment.
This high-quality metal lends itself to being made into carbon structure steel, cold heading steel (cold pressing discrete configurations from a steel blank or slug), welding rod, and steel stranded wire as used in steel belted radial tires, suspension bridges, and engineered springs used in automotive or industrial-type machines. Longhai Steel also offers its products to third-party processors who turn out such useful things as nails, the wire mesh used in reinforced concrete, hardware cloth, and the linked mesh that makes up chain link fencing.
The company recently capitalized on its superb reputation for exceeding PRC quality standards in the 6.5mm to 10mm wire metric, so widely used in the construction industry, via an additional production facility in Xingtai. This ultra-modern, high-speed plant not only has increased capacity, but has a longer production line equipped with advanced heating and cooling systems that result in a more durable and reliable product. In addition, this new facility is geared to roll out the kind of higher margin, 5.5mm to 18mm steel wire needed for specialized products.
Thanks to increased production and higher quality processes, Longhai Steel looks to secure an increasing slice of the regional stranded steel wire marketplace as increasing demand – sparked by local infrastructure upgrades and improvements – spurs development of the tier 3-6 city construction initiative which offers a firm foundation for growth.
Longhai Steel’s production improvements and expanded capacity offer the company an opportunity to effect a consolidation strategy which, aligned with PRC policy initiatives, promises to bring together an industry which has grown up piecemeal. The consolidation, in turn, is an opportunity for Longhai Steel to vertically integrate its business in a fusion of strategic acquisitions that has (and will) prove valuable for LGHS shareholders.
These policies, which anticipate China’s emergence as a major player in the global steel marketplace (with an increase in steel production of four percent even as the rest of the world shows declines of 1.2 percent), are available to Longhai Steel through corporate practices which favor long-term customer relationships, superior quality, rapid turnaround, reliable delivery, and customer support – all driven by economies of scale and acquisition opportunities which will reduce obsolete production capacity, promote cost reduction strategies and increase energy efficiency in an industry which has been seriously fragmented by rapid buildout.
Even though China is experiencing some of the slowdown occupying Western construction markets, it continues to roll out infrastructure at a fever pace, driving a remarkable 45 percent of global steel production and 46 percent of global steel consumption in 2011. Hebei Province, the steel capital of China’s northeast, in 2011 accounted for 20 percent of total nationwide steel output.
An overview of market opportunities in China show the government instituting policies designed to divide 60 percent of domestic steel capacity among the top 10 producers by 2015, as opposed to a mere 44 percent in 2009.
This intense consolidation is one metric in those economies of scale that promises to leverage the inherent value of China’s huge stimulus package, which offers $586 billion to create significant steel demand via increased construction in housing, roads, highways, dams, irrigation projects, airports, and other infrastructure buildouts.
Longhai Steel’s new 200,000 square-meter location, which includes everything from production lines and warehousing to company office space, make it even easier for the company to provide rapid turnaround and delivery on orders across a wider product mix.
To learn more about the company, visit www.longhaisteelinc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Friday, August 24, 2012
Daystar Technologies, Inc. (DSTI) Completes Assembly of Senior Management Team
Daystar Technologies is a developer of solar photovoltaic products based upon GIGS thin film deposition technology and is currently implementing a strategy of using key partnerships to enter new markets in the renewable energy marketplace.
The company announced today that it has substantially completed assembling its new senior management team who will join Chairman of the Board and interim CEO, Peter Lacey. The new team members are: Dale Hoover, vice-president and chief financial officer; Xinneng (David) Li, executive vice-president; Joseph Hunsberger, vice-president of operations; and Dan Giesbrecht, vice-president of business development and marketing.
Mr, Hoover was formerly with Tutor Perini Corporation, a publicly traded general contractor, from 2006 to 2012. He provided executive financial leadership for the firm thanks to his expertise in financial reporting and GAAP, treasury and cash management, budgeting and forecasting, job profit status, and reducing costs. Mr. Hoover is also proficient in taxes, contracts, financing deals, due diligence, risk management, IT services, and staff recruitment/training.
Mr. Li was formerly with Selwyn Chihong Mining Limited where he provided executive financial expertise and fundraising for one of the world’s largest zinc and lead projects in northern Canada. His past experience also includes 2 years with Trina Solar where he led the strategic planning and strategic financial development. Mr, Li also worked with Cargill and assisted one of the world’s biggest firms in strategic business development, joint venture setup, and government relations management.
Mr. Hunsberger was formerly with The Home Depot for 17 years as the director of services and divisional manager. He has an exceptional record of success and performance across comprehensive business development and managerial functions. While at Home Depot, Mr. Hunsberger was the sole architect in the creation, development, training, and implementation of the ‘Installation and Home Services Division of The Home Depot’, building from zero to $3.5 billion in sales.
Mr. Giesbrecht was formerly with Sunlogics, Inc. as the director of business development. He has extensive experience in solar energy specializing in construction management and acquisition of renewable energy projects. Mr. Giesbrecht also served as the North American sales manager for Sunlogics where his primary role was to see that the solar canopy division worked properly in implementation of the General Motors dealership program.
For additional information about Daystar Technologies, please visit the company’s website at www.daystartech.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
ZELTIQ Aesthetics, Inc. (ZLTQ) Places 25-Year Medical Device and Venture Capital Sector Veteran Mark J. Foley in CEO, President Role
ZELTIQ Aesthetics, the medical technology company which developed the innovative CoolSculpting® System designed to target and reduce stubborn fat bulges (using a simple non-invasive 60-minute procedure) that don’t respond to amelioration via diet and exercise, announced the appointment today of 25-year industry veteran Mark J. Foley to the role of President and full-time CEO.
This is a step up for Foley, who has held the Interim President and CEO slot up until now, also serving on the company’s Board since back in 2009, with a stint as Executive Chairman up until early 2010. Foley brings considerable experience to the role, gathered from such ongoing engagements as being Managing Director at early-stage tech venture capital firm, RWI Ventures, as well as Executive Chairman at Onpharma, Senior Advisor to the TauTona Group, and a Director for both Sonitus Medical and Voyage Medical.
This kind of deep field experience has seen Foley in senior operating, investment, and board positions at large cap medical device sector companies for decades and his CEO capabilities have been made abundantly clear. With a great deal of work in venture-backed early stage development on success stories like Ventrica (of which Foley was Founder and CEO), which was later acquired by major player Medtronic, the appointment is a shrewd play by ZLTQ to kick start the next level of commercialization for their proprietary controlled-cooling technology and the CoolSculpting System. The list of successful start-ups Foley has under his belt is quite impressive and includes prominent examples like Guidant, US Surgical Corp., and DVI, later acquired by juggernaut Eli Lilly, and Perclose, which was acquired by Abbott.
Mark asserted that his long history with the company and familiarization with every aspect of the technology has placed him in the pole position to execute on growing the CoolSculpting market. Currently in a leadership position in the non-invasive fat reduction space, this remarkable technology is a clinically proven, FDA-cleared, and totally non-surgical solution to unsightly stubborn fat accumulation that has customers out the door fast with no downtime (as opposed to existing solutions that require healing or recuperation of some sort). CoolSculpting is extremely accurate and targets only the intended fat cells using a patented procedure that was developed by Harvard scientists, whereby fat cells are crystallized and then later break down over a period of a few months, the cell constituents naturally eliminated or otherwise reabsorbed by the body, leaving healthy skin and other cells unaltered.
Foley (B.A., University of Notre Dame) noted that the proven safety of the CoolSculpting technology and demonstrated efficacy in some 400k procedures to date granted ZLTQ a huge inroad to capitalize on their lead position in the market, as this incredible technology accumulates broader market impact.
Chairman of ZLTQ’s Nominating and Governance Committee, Bryan Roberts, Ph.D., a Partner over at technology, healthcare, and energy focused venture cap firm Venrock, was delighted at the permanent-basis CEO appointment of Foley, whom he regards as possessing an “in-depth understanding” of the company’s business, technology platform, and growth strategy. The logistics of that growth strategy are immediately apparent to a seasoned pro like Foley, and ZLTQ will be looking to extend significant Q2 performance with increased market penetration, aided by the vision of this born leader.
For more information on this key appointment, or to learn more about ZELTIQ Aesthetics, Inc., please visit the company’s website at: www.CoolSculpting.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
CareView Communications, Inc. (CRVW) Continues to Extend Market Reach in Southern Cali with Monrovia Memorial Hospital Agreement
CareView Communications, an information technology provider to the healthcare industry, is the creator of a proprietary high-speed data network system designed to operate throughout a healthcare facility’s existing cable television infrastructure. The company today said it has inked an agreement with Monrovia Memorial Hospital in southern California to supply the hospital with the CareView system.
CareView’s Room Control Platform and related software applications provide real-time bedside monitoring and point-of-care video monitoring and recording to improve patient safety. Ron Kupferstein, CEO of Monrovia, said the technology is complementary to the hospital’s mission.
“We recently completed a total renovation of our hospital. We believe the installation of the CareView System will help us maintain our vision of being a hospital where technology meets compassion and patients always come first,” Kupferstein stated in the press release.
CareView has already installed its systems in several hospitals in southern California as part of its strategy to extend its market reach, and the company plans to launch an aggressive marketing campaign in September, targeting the southern region of the state.
Samuel A. Greco, CareView’s CEO, said the company has received favorable results and feedback from its current customer base and that several well-respected hospitals have expressed their intent to utilize the company’s technology.
“Over the past couple of years, our CareView System has proven very successful based on the positive feedback we have received from our participating hospital groups. It is now time for us to demonstrate that our technology is a necessary component in every hospital’s plan to deliver quality healthcare to patients in the safest environment possible,” Greco stated.
For more information visit www.care-view.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Cardium Therapeutics, Inc. (CXM) Has New Bio-Assay Test to Support Commercialization of Generx
Cardium Therapeutics, a San Diego based medical technology company, working with Michigan based Essen Bioscience, Inc., has come up with an important new bio-assay potency test for use with Generx, the company’s advanced clinical stage product candidate. For use by interventional cardiologists, Generx is a gene therapy that utilizes the body’s natural healing potential to grow microvascular blood vessels in the hearts of patients suffering from coronary artery disease.
An article in San Diego Biotechnology Connection describes how the new bio-assay and visualization test measures the formation and growth of blood vessels from Generx-derived proteins in cell cultures. Although Cardium has already developed the necessary tests for product release, the new test goes beyond FDA guidelines and supports Cardium’s ongoing efforts to commercialize Generx. Specifically, the new assay evaluates and confirms the actual biological angiogenic capacity of each Generx production batch, and sets a new global standard in the field of regenerative medicine that now encompasses gene, cell, and stem cell therapies.
Generx is designed as a one-time non-surgical product, delivering a DNA-based biologic to the heart using an angiographic catheter. It’s an approach of special value in countries with high cardiovascular death rates, where the infrastructure and economics needed for more costly and invasive surgical revascularization procedures, such as coronary artery bypass surgery and angioplasty/stents, may not be readily available. Cardium is currently focusing their commercialization efforts for Generx on Russia and other parts of the international market. Generx is currently being evaluated in the Phase 3 ASPIRE trial in medical centers in Moscow and St. Petersburg. Clinical sites are currently enrolling the 100 heart disease patients needed for the trial.
The European Medicines Agency’s Committee for Medicinal Products recently recommended the authorization of Glybera, a first for a gene therapy product, which offers encouragement for products like Generx.
For additional information, visit www.CardiumTHX.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Onstream Media Corp. (ONSM) Announces Launch of MarketPlace365® Mobile App, Delivering Virtual Events on a Mobile Platform
Onstream Media, a prominent online service provider of on-demand and live corporate audio and web communications, virtual event technology, and social media marketing, announced today that it has launched MarketPlace365 Mobile App, the company’s first virtual event smartphone app. This impressive app is the mobile form of Onstream Media’s MarketPlace365 virtual event platform, and is now available for download on the Apple App Store and Google Play/Android Market.
“MarketPlace365 is a versatile tool that can be used by event organizers, tradeshow planners and corporations to host webcasts, web conferences, trade shows and permanent marketplaces. Now, organizers can open up participation in their events to audiences on phones and tablets, as well as to those on computers,” said Randy Selman, President and CEO of Onstream Media. “This provides organizers with a significantly greater ability to increase engagement, generate leads and grow revenue.”
The MarketPlace365 Mobile App is a pioneer in the mobile app landscape by using Onstream Media’s advanced encoding to become one of the only virtual event apps to deliver a virtual environment with streaming video content on both the Android and Apple platforms.
Event organizers can create their own event-specific versions of the MarketPlace365 Mobile App, and make it available to download, free or with a fee for participation. For end users, the cost of the app will be governed by the cost of the events in which they participate. However, the basic app can be downloaded for free from Apple App Store and Google Play.
The MarketPlace365 platform and mobile app offer multiple “rooms,” that can be applied individually or in unison. Among the rooms available are the Exhibition Hall, Auditorium, Learning Center, Media Library, and Lounge. Within each room, users can interact with exhibitors, listen to speakers, participate in interactive sessions, download materials, and collaborate with others. Additionally, the platform incorporates social networking, chats, and Q&A sessions.
MarketPlace365 can be used to offer a purely virtual event, or to extend the reach of a physical event. A hybrid event, for instance, can allow a tradeshow participant to walk around a physical show with his or her iPad, and use the app to learn about exhibitors, download information, or make appointments.
“The MarketPlace365 Mobile App means that people who want to participate in virtual events no longer need to be tethered to their desktops. This dramatically increases their ability to use their time productively, and to gain access to content that will benefit their businesses,” said Selman. “Corporations, publishers, show organizers and others can now provide content to their audiences in the way their audiences want to consume it.”
For further information, please visit www.onstreammedia.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Alphatec Holdings, Inc. (ATEC) Subsidiary Launches BridgePoint Spinous Process Fixation System
Alphatec Holdings, parent company of Alphatec Spine, has announced the launch of its latest minimally invasive surgery (MIS) device, the BridgePoint Spinous Process Fixation System.
This system is designed to allow spinal surgeons to immobilize and stabilize spinal segments without using pedicle screw and rod constructs. The BridgePoint System is intended as an adjunct to fusion of the thoracic and lumbar spine to treat disorders that result from degenerative disc disease, spondylolisthesis, tumor, and trauma. The MIS device has the capability of helping patients suffering with chronic back pain to regain their active lifestyles.
Designed to be implanted through a relatively small posterior incision of around 5 centimeters in length, BridgePoint is intended to result in less muscle and tissue injury and less blood loss than occurs with implantation of traditional pedicle screw and rod systems through a non-MIS approach. MIS procedures are also generally shorter time-wise, conserving valuable surgeon and hospital time and resulting in faster patient recovery times and fewer complications.
The design of the BridgePoint System incorporates telescoping plates that enable surgeons to compress or distract the spinous processes before immobilizing the spinal segment. The large contact area of the device supplies a strong anchor point to each spinous process, facilitating compression, or distraction and optimal stability during the fusion process. The BridgePoint System can be used as an adjunct to interbody fusion or posterior fusion with decompression treatment. The large bone graft window enables surgeons to pack additional bone graft between the spinous processes.
The first BridgePoint implantation case took place in August 2012 at Cheyenne Regional Medical Center in Cheyenne, Wyo., and was conducted by board certified neurological surgeon Dr. Steven Beer. BridgePoint provided a way for Dr. Beer to less invasively treat a patient with degenerative disc disease and spinal stenosis. The system allowed him to more efficiently fixate the spine and also made the surgery safer and faster.
It is anticipated that the market for spinous process fixation devices will reach $206 million by 2016, growing at a compound rate of more than 24 percent from 2008.
Alphatec Spine specializes in designing, developing, manufacturing, and marketing products for the surgical treatment of spine disorders, primarily focused on the aging spine. The company aims to combine world-class customer service with pioneering, surgeon-driven products that help improve the aging patient’s quality of life. Alphatec Spine is positioned to achieve this goal through new solutions for patients with osteoporosis, stenosis, and other aging spine deformities, as well as through offering improved minimally invasive products and techniques and integrated biologics solutions. In addition to operations in the United States, the company markets its products in 50 international markets.
For more information, visit the company’s Web site at www.alphatecspine.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Subscribe to:
Posts (Atom)